Regal Healthcare Capital Partners
Regal Healthcare Capital Partners focuses exclusively on healthcare services and describes a control growth equity and buyout strategy for smaller lower-middle-market companies. Its stated targets include businesses with $20M-$100M of revenue, $2M-$10M of EBITDA, and a typical equity investment size of $30M-$70M.
What stands out about Regal Healthcare Capital Partners
Regal Healthcare Capital Partners publicly targets multi-site and/or provider-led healthcare-services businesses in fragmented sectors, with $20M-$100M of revenue and $2M-$10M of EBITDA. It combines financial backing with operational expertise and states a typical equity investment size of $30M-$70M.[1][2][4][5][7]
What does Regal Healthcare Capital Partners invest in?
Regal Healthcare Capital Partners describes itself as a control growth equity and buyout firm specializing in the smaller end of lower-middle-market healthcare services companies. It states that it combines financial backing with operational expertise to help healthcare entrepreneurs accelerate growth.[1]
Regal states that it invests exclusively in healthcare services and partners with entrepreneurs in fragmented healthcare sectors. Its stated strategy is directed toward control growth equity and buyout investing in the smaller end of the lower middle market.[1]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Regal Healthcare Capital Partners?
For an owner of a healthcare-services company, the published criteria point to businesses with $20M-$100M of revenue, $2M-$10M of EBITDA, multi-site and/or provider-led operations, and exposure to fragmented healthcare sectors. Regal also describes operational capabilities covering data analytics, KPI dashboards, clinic-location analysis, predictive staffing analytics, provider alignment, clinical leadership, provider incentives, and patient-satisfaction measurement.
Owners should clarify how Regal’s current strategy applies to control, rollover equity, governance, ownership duration, valuation, financing, management retention, and operating autonomy.[1][4]
What is the expected investment horizon and exit process
Regal’s About page does not state an expected ownership duration, investment horizon, or exit timing for portfolio investments.[1]
What companies does Regal Healthcare Capital Partners target?
Regal publicly targets companies with $20M-$100M of revenue, $2M-$10M of EBITDA, and a typical equity investment size of $30M-$70M. Its stated target characteristics include high clinical quality and patient focus, experienced senior management, regional leadership, strong industry dynamics, fragmented markets, and management alignment.[1][4]
Regal’s public portfolio-sector descriptions include autism, dental, dermatology, emergency-room management, fertility, healthcare staffing, in-home healthcare, mental health, non-medical home care, psychiatric crisis, outpatient behavioral health, eyecare, and kidney-disease management.[2]
Regal identifies itself as a New York-based healthcare private equity firm.[3]
Regal’s public materials describe a control growth equity and buyout strategy and include a public announcement describing the formation of InFocus Eyecare.[1][5]
In June 2022, Regal announced the formation of InFocus Eyecare with Ryan Williams and his executive team. Regal also stated that it invested in Thriveworks in November 2019 and remained Thriveworks MSO’s largest equity holder following a financing led by Wellington Management in July 2021.
In July 2021, Regal announced that Dental365 would be acquired by The Jordan Company and that Regal and its founders would remain minority investors.[5][6][7]
Regal announced the July 7, 2026 final close of RHCP IV at $610 million of total commitments, including approximately $575 million of external commitments against an original target of $550 million.
Other public transaction examples include the June 2022 formation of InFocus Eyecare, Regal’s investment in Thriveworks and continued equity position following its July 2021 financing, and the July 2021 announcement that Dental365 would be acquired by The Jordan Company with Regal and its founders remaining minority investors.[3][5][6][7]
What is not clear from Regal Healthcare Capital Partners's public investment criteria?
Regal’s About page does not state an expected ownership duration, investment horizon, or exit timing for portfolio investments.
The InFocus Eyecare announcement does not disclose transaction consideration or a closing date. The Dental365 announcement does not disclose transaction consideration or a completed closing date; it states only that the transaction was expected to close in August.
Regal’s portfolio page presents sector descriptions but does not name portfolio companies on that page itself.[1][2][5][7]
Questions to ask when evaluating Regal Healthcare Capital Partners as a buyer or investment partner
Does Regal require control for the current strategy, or does it accept minority investments?
What percentage of equity does Regal typically acquire, and what rollover is expected from selling owners?
What is the expected investment horizon and exit process?
Regal’s About page does not state an expected ownership duration, investment horizon, or exit timing for portfolio investments.[1]
How are clinical quality, provider alignment, reimbursement exposure, and patient outcomes evaluated?
Regal identifies clinical quality, patient focus, provider-led businesses, reimbursement-risk exposure, and provider alignment among its stated investment or value-creation considerations.[1]
Which operating resources are available to a portfolio company?
Regal describes value-creation capabilities that include data analytics, KPI dashboards, clinic-location analysis, predictive staffing analytics, clinical leadership, provider incentives, and patient-satisfaction measurement.[1]
What are the governance, management-retention, earnout, indemnity, and post-transaction employment expectations?
Regal lists management alignment among its target-investment characteristics, but the published target characteristics do not establish the governance or employment terms for a particular transaction.[1]
Sources & research notes
- Official website / firm overview
- Industry / market focus
- Geography / market coverage
- Transaction size / criteria
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- SEC filing / regulatory record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.